Is the use of RAS inhibitors safe in the current era of COVID-19 pandemic?
2019 novel coronavirus
ACE inhibitor
ACE2
Angiotensin receptor blocker
Antihypertensive drugs
COVID-19
Hypertension
Infection
Pandemic
SARS
SARS-CoV-2
Sepsis
Journal
Clinical hypertension
ISSN: 2056-5909
Titre abrégé: Clin Hypertens
Pays: England
ID NLM: 101669508
Informations de publication
Date de publication:
2020
2020
Historique:
received:
24
03
2020
accepted:
02
04
2020
entrez:
12
5
2020
pubmed:
12
5
2020
medline:
12
5
2020
Statut:
epublish
Résumé
Antihypertensive drugs are one of the most widely used pharmacologic agent in the world and it is predominantly used in the elderly subjects. Pneumonia is the most common cause of death in the extremely old subject. During infection and its complication such as sepsis, hypotension could be exacerbated by antihypertensive drugs because homeostasis mechanisms such as sodium balance, renin angiotensin aldosterone system and/or sympathetic nervous system can be mitigated by antihypertensive drug therapy. Severe Acute Respiratory Syndrome-Coronavirus-1 and 2 viral surface protein is known to attach angiotensin converting enzyme 2 (ACE2) on the cell membrane to facilitate viral entry into the cytoplasm. Despite the theoretical concerns of increased ACE2 expression by Renin-Angiotensin-Aldosterone system (RAS) blockade, there is no evidence that RAS inhibitors are harmful during COVID-19 infection and have in fact been shown to be beneficial in animal studies. Therefore, it is recommended to maintain RAS blockade during the current corona virus pandemic.
Identifiants
pubmed: 32391169
doi: 10.1186/s40885-020-00144-0
pii: 144
pmc: PMC7202902
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
11Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsPark S received honoraria from Dai ichi Sankyo, Servier, Takeda, Boryung pharmaceutical company, Daewoong and Dong-A ST. HY Lee received honoraria from Dai ichi Sankyo, Servier, Takeda, Boryung Pharm., Daewoong, and Dong-A ST; DH Kim received honoraria from Sankyo, Servier, Takeda, Boryung Pharm., Daewoong, and Dong- ST; IS Sohn received grants from Hanmi. Pharm. and honoraria form Sankyo, Boryung, and Dong-A ST; WJ Chung received honoraria from Norvatis, Servier, Dong-A ST, Takeda, Boryung, and Hanmi Pharm.; J Shin received grants from Hanmi Pharm. and Sanifi and honoraria from Sankyo, Boryung, and Menarini. EJ Cho, KC Sung, J Kim, SH Ihm, K Kim, SK Ryu, WB Pyun, and HC Kim have no conflicts of interest.
Références
J Virol. 2014 Jan;88(2):1293-307
pubmed: 24227843
JACC Heart Fail. 2015 Aug;3(8):647-53
pubmed: 26251094
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Hypertension. 2014 Dec;64(6):1368-1375
pubmed: 25225202
Hypertension. 2020 Feb;75(2):483-491
pubmed: 31838905
J Pathol. 2004 Jun;203(2):631-7
pubmed: 15141377
Korean Circ J. 2019 Jan;49(1):22-45
pubmed: 30637994
Medicine (Baltimore). 2020 Jan;99(4):e18961
pubmed: 31977913
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Eur Heart J. 2005 Feb;26(4):369-75; discussion 322-4
pubmed: 15671045
Europace. 2017 Aug 01;19(8):1280-1287
pubmed: 27738071
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Thorax. 2007 Jan;62 Suppl 1:1-46
pubmed: 17202446
Pharmacol Rev. 2019 Oct;71(4):539-570
pubmed: 31537750
J Am Heart Assoc. 2017 Feb 11;6(2):
pubmed: 28189999
Nature. 2005 Jul 7;436(7047):112-6
pubmed: 16001071
Intensive Care Med Exp. 2015 Dec;3(1):44
pubmed: 26215809
Am J Respir Crit Care Med. 2004 May 1;169(9):1041-5
pubmed: 14990394
Nat Med. 2005 Aug;11(8):875-9
pubmed: 16007097
J Biol Chem. 2000 Oct 27;275(43):33238-43
pubmed: 10924499